An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference scaled Oral Bioequivalence Study Comparing Valsartan and Hydrochlorothiazide Tablets USP 320 mg and 25 mg Manufactured by Incepta Pharmaceuticals Ltd Incepta Bioscience Division with Diovan HCT Valsartan and Hydrochlorothiazide Tablets USP 320 mg and 25 mg Distributed by Novartis Pharmaceuticals Corporation East Hanover New Jersey 07936 In Healthy Adult Human Subjects Under Fasting Conditions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To assess the Bioequivalence on Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg Manufactured by Incepta Pharmaceuticals Ltd Incepta Bioscience Division Dhamrai Dhaka Bangladesh with Diovan HCT Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg Distributed by Novartis Pharmaceuticals Corporation East Hanover New Jersey 07936 In Healthy Adult Human Subjects Under fasting Conditions
研究概览
简要总结
At least 60 number of healthy adult human subjects will be recruited to evaluate the Bioequivalence of Test product with the Reference product.
As per the discretion of the Investigator a sufficient number of stand-by subjects will be included additionally to ensure successful dosing of 60 subjects in period I alone
If needed the study will be conducted as batch wise
Equal number of male & female volunteers will be recruited to conducted the study
In each period subjects will be housed in the clinical facility for at least 11.00 hours pre-dose to 48.00 hours post-dose A washout period of at least 07 days between the successive dosing days
In each period after an overnight fasting of at least 10.00 hours in the morning a single oral dose of either the test product T or reference product R will be administered as per the randomization schedule
Blood pressure radial pulse rate body temperature and wellbeing status will be enquired and recorded at pre-dose 00.00 hour within 75 minutes of before dosing and at 01.00 02.00 04.00 06.00 08.00 12.00 24.00 and 36.00 hours ± 60 minutes post-dose
Monitoring for adverse events will be done throughout the study period in clinical phase
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 45.00 Year(s)（—）
- 性别
- All
入选标准
- •Normal healthy adult human male and female subjects of age between 18 to 45 years and Body Mass Index BMI ranges between 18.50 kg per m2 to 30.00 kg per m2 Subjects who have no evidence of underlying disease during screening and check in and whose screening is performed within 21 days of check in Subjects whose screening laboratory values are within normal limits are considered by the physician or principal or clinical investigator to be of no clinical significance Healthy as documented by the medical history physical examination including but not limited to an evaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervous system and vital sign assessments Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinical laboratory assessments Willing to consume non vegetarian diet and Standard Light breakfast Willing to comply with all requirements of this study protocol as well as instructions from the study personnel Non smokers Generally healthy, as documented by gynaecological examination and breast examination period I only Females of childbearing potential must have a negative serum pregnancy test performed within 21 days prior to the initiation of the study and a negative urine pregnancy test prior to check in for each period If the subject is female currently not pregnant not lactating or not attempting to become pregnant for 4 weeks before the screening visit throughout the duration of the study and 3 weeks after the subjects last study related visit for eligible subjects only if applicable has a negative serum pregnancy test and is of non-childbearing potential defined as greater or equal to 01 year post menopausal no menstrual period for at least 12 consecutive months without any other medical cause Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy or is of childbearing potential willing to commit to using a consistent and acceptable method of birth control as defined below for the duration of the study double barrier methods condoms cervical cap diaphragm and vaginal contraceptive film with spermicide intrauterine device IUD with a low failure rate of less than 1 percentage per year or is of childbearing potential and not sexually active willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study in the event the subject becomes sexually active.
排除标准
- •Evidence of allergy or known hypersensitivity to Valsartan and hydrochlorothiazide or its inactive ingredients Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre-existing gallbladder disease Any major illness in the last three months or any significant ongoing chronic medical illness Renal or liver impairment Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis History of alcohol addiction or abuse Consumption of caffeine and /or xanthine containing products ie coffee tea chocolate caffeine containing sodas colas etc cigarettes and tobacco containing products for at least 48.00 hours prior to check in and throughout the entire study Consumption of alcohol and its products grapefruit and or its juice and poppy containing foods within 48.00 hours prior to clinic admission and throughout the entire study Subjects who have taken any prescription medications within 14 days prior to study check-in and throughout the study and any over the counter medicinal products herbal medications within 07 days prior to study check in and throughout the study Subjects who have taken any unusual diet for whatever reason eg low salt for 48.00 hours prior to dosing and throughout the study Subject who had participated in any other study within the 90 days of check in History of difficulty in swallowing History of difficulty in accessibility of veins Positive results for urine screen of drugs of abuse Marijuana THC amphetamine AMP barbiturates BAR cocaine COC benzodiazepines BZD and morphine MOR in urine prior to check in of each period Positive results for alcohol test prior to check-in of each period Any blood donation excess blood loss within 90 days of check-in Ingestion of any hormonal agent at any time within 14 days prior to the start of the study check-in Use of hormone replacement therapy for a period of 06 months prior to dosing Female subjects demonstrating a positive pregnancy screen Female subjects who are currently lactating Females are likely to become pregnant during the course of the study.
结局指标
主要结局
To assess the Bioequivalence on Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg Manufactured by Incepta Pharmaceuticals Ltd Incepta Bioscience Division Dhamrai Dhaka Bangladesh with Diovan HCT Valsartan/Hydrochlorothiazide Tablets USP 320 mg/25 mg Distributed by Novartis Pharmaceuticals Corporation East Hanover New Jersey 07936 In Healthy Adult Human Subjects Under fasting Conditions
时间窗: 23 Time Points | 00 00 hrs 00 50 hrs 01 00 hrs 01 33 hrs 01 67 hrs 02 00 hrs 02 33 hrs 02 67 hrs 03 00 hrs 03 33 hrs 03 67 hrs 04 00 hrs 04 33 hrs 04 67 hrs 05 00 hrs 05 50 hrs 06 00 hrs 07 00 hrs 08 00 hrs 10 00 hrs 12 00 hrs 24 00 and 48 00 hrs
次要结局
- To monitor the safety and tolerability of test product comparing with the reference product in healthy, adult, human subjects under fasting conditions(23 Time Points)
研究者
Dr Pradeep T
Spinos Lifescience and research private limited